Biotech

All Articles

TPG tops up funds to $580M for investments all over lifestyle sciences

.Resource manager TPG, which has actually supported biotechs including Sionna Therapeutics as well a...

Merck stops phase 3 TIGIT trial in lung cancer cells for impossibility

.Merck &amp Co.'s TIGIT program has gone through yet another setback. Months after shuttering a phas...

After a tough year, Exscientia folds up in to Recursion

.After a year described by pipe hairstyles, the shift of its own chief executive officer and also di...

Cullinan, after $25M deal, restore bispecific to Harbour

.Cullinan Therapeutics was impressed good enough along with Port BioMed's bispecific immune reactor ...

A deeper take a look at Ferocious Biotech's Ferocious 15

.In this full week's incident of "The Top Line," our experts're diving in to Tough Biotech's annual ...

Lilly deals with period 2 failing of tau-targeting med

.The confetti is still flying from Eli Lilly's event commemorating the commendation of Alzheimer's h...

Biogen CMO Maha Radhakrishnan participates in Sofinnova-- Chutes &amp Ladders

.Welcome to today's Chutes &amp Ladders, our summary of significant leadership hirings, firings and ...

Lykos will definitely inquire FDA to reconsider its selection following turndown of MDMA therapy for trauma

.Complying with an unsatisfactory revealing for Lykos Rehabs' MDMA prospect for post-traumatic stres...

AN 2 one-halfs headcount, quits stage 3 test after information disappoint

.AN2 Rehabs is rethinking its own business in response to poor midphase data, swearing to lay off ha...

Merck spends $700M for bispecific, snooping autoimmune opening and odds to challenge Amgen in cancer cells

.Merck &amp Co. is paying out $700 thousand beforehand to test Amgen in a blood stream cancer market...